Articles tagged with Antigens
Researchers have designed a new nanoparticle adjuvant that significantly improves antibody production following vaccination against HIV, diphtheria, and influenza. The adjuvant speeds up lymph flow to lymph nodes, helps antigens reach B cells before breaking down, and activates inflammatory cytokines for a stronger response.
Antibodies that mimic the SARS-CoV-2 virus may explain lingering symptoms of long-haul COVID-19 and rare vaccine side effects like allergic reactions and blood-clotting. This theory, based on classic immunological concepts, suggests a cascade of immune responses that can lead to adverse effects.
Researchers found that omitting or altering the buffer solution can generate false positive results, highlighting its essential role in test function. The study's findings have far-reaching implications for public health worldwide, as the rapid antigen test has been distributed to over 120 countries.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
Researchers found that prior MMR or Tdap vaccination was associated with decreased disease severity in COVID-19 patients. The study suggests that these commonly given vaccines may protect against severe COVID-19 disease, emphasizing the importance of routine vaccination for children and adults.
A study found that SARS-CoV-2 antibodies remained stable or increased in healthcare workers seven months after infection, indicating potential protection from pre-existing antibodies against common cold coronaviruses. The results suggest that individuals with higher levels of anti-HCoV IgG and IgA had lower susceptibility to COVID-19.
A new biomarker, HBcrAg, has been found to accurately predict viral load in patients with chronic hepatitis B and reflect response to anti-viral treatments. This discovery may lead to improved monitoring methods for CHB, enabling clinical decisions and potentially improving patient outcomes.
Researchers have developed nanobodies that target the cytomegalovirus (HCMV), a virus that can cause life-threatening complications in immunocompromised patients. These nanobodies bind to the US28 protein and interrupt signals that keep the virus dormant, enabling the immune system to detect and destroy the virus.
Researchers investigated CEA as a blood-based biomarker for anal cancer. Although CEA levels correlated with disease progression, they were not associated with survival outcomes or clinically relevant in managing the disease. Novel approaches with serum biomarkers are necessary for this rare and increasing diagnosed malignancy.
Researchers developed hybrid membrane nanovaccines that educate patients' immune systems to distinguish tumor components as 'non-self', preventing recurrence and metastasis. The vaccines induce robust innate and adaptive immune responses, offering a new opportunity for individualized cancer vaccines.
Researchers developed a novel immunosensor called BRET Q-body, which works on the bioluminescence resonance energy transfer principle. The sensor detects antigens by inducing fluorescence through an enzyme-luminescent substrate reaction, allowing for simple and accurate immunoassay tests.
Researchers found that T cells can make mistakes when identifying healthy cells from infected ones, even when binding tightly to antigens. This discovery may lead to new treatments for autoimmune diseases and improve cancer therapies.
A new x-ray technique developed by Berkeley Lab scientists may revolutionize COVID-19 testing. The method uses small angle X-ray scattering to identify highly sensitive antibody pairs for detection, promising fast and accurate results.
Researchers at UC Santa Cruz developed a novel chip-based antigen test that can detect individual viral antigens one by one in nasal swab samples, enabling simultaneous testing for multiple viruses from one sample. The test's ultrasensitive technique could eventually be developed as a molecular diagnostic tool for point-of-care use.
A new stem cell-based vaccine has demonstrated 75% protection against pancreatic cancer in a mouse study. The vaccine targets multiple antigens found on pancreatic cancer cells, potentially leading to a more durable immune response.
Researchers observed T cells exerting a tiny force of up to 5 pico-newtons when recognizing antigens, allowing them to determine if the interaction is with the desired antigen. This study provides insights into how T cells function at the molecular level and could lead to significant advances in medicine.
A prospective study found serial antigen testing can be an effective strategy for controlling infection during a SARS-CoV-2 outbreak in nursing homes. The test was less sensitive than RT-PCR but performed well in identifying early infections and replicative viruses.
Mass testing campaigns in Slovakia significantly decreased SARS-CoV-2 infection rates, with the highest reductions observed in high-prevalence counties. The study found that rapid antigen testing, combined with isolation of those who tested positive, resulted in a substantial decrease in transmission
A new study led by Yale University suggests that home testing for SARS-CoV-2 could significantly reduce total infections and mortality at a reasonable cost. By providing households with rapid antigen tests to identify potential contagion, individuals can self-isolate before spreading the disease.
A new study suggests a potential link between blood group A and COVID-19 infection, with the SARS-CoV-2 virus preferring to bind to the A antigen found on respiratory cells. The study's findings could provide insight into how coronaviruses like SARS-CoV-2 interact with different blood types.
Research on T cells reveals that prolonged exposure to antigens can lead to exhaustion, reducing their ability to contribute to immune responses. A new model study identifies dynamic adjustments in T helper cells' states of exhaustion and suggests potential therapeutic targets.
Researchers have identified a mechanism that allows Trypanosoma brucei to express only one surface protein variant, avoiding detection by the immune system. This finding has implications for understanding and potentially inhibiting antigenic variation in pathogens.
Researchers developed an mRNA vaccine that restored tolerance to self-proteins in mice with autoimmune encephalomyelitis, a mouse model for multiple sclerosis. The vaccine suppressed immune responses and promoted regulatory T cells to control the disease.
Researchers at TU Wien have discovered that tiny traction forces on the molecular level are essential for the recognition of antigens by T-cells. This new understanding could lead to a deeper understanding of immune system function and potentially new treatment strategies.
A study found that supervised, self-administered swabs were as effective as professional-collected nasopharyngeal swabs in detecting SARS-CoV-2 infections. The researchers identified cases where antigen tests missed infections were associated with low viral loads, but correctly identified high-load samples.
A study published in the Journal of Experimental Medicine reveals that inhibiting protein OCA-B protects mice from type 1 diabetes by limiting immune cell activity. The finding provides a proof-of-principle for OCA-B as a therapeutic target and could lead to further development of treatments.
A semiconductor chip has been developed to detect antigen concentrations as low as 1 part per quadrillion molar mass, enabling ultra-sensitive detection on a portable scale. This technology uses organic nanosheets and can detect biomolecules in real-time, paving the way for quick disease diagnosis and telemedicine applications.
Researchers combine machine learning with cell engineering to create living medicines that selectively kill cancer cells while leaving normal tissue unscathed. By analyzing massive databases of proteins, they assemble a catalog of combinations that can precisely target tumors, overcoming the limitations of current treatments.
Researchers have developed an immunotherapy approach that specifically impedes the autoimmune response driving MS, while preserving the rest of the immune system. In mouse models, the therapy prevented disease onset and reduced severity after disease onset.
Researchers found stable antibody titers in mild-to-moderate COVID-19 patients for at least five months. The study suggests that these long-lasting antibodies may protect against reinfection and attenuate disease severity.
Researchers from Texas A&M University have made significant discoveries on how the immune system detects hidden intruders. The study found that T-cells increase their detection power mechanically, using a 'catch bond' between T-cell receptors and MHC molecules when force is applied.
Researchers developed a polymer-nanoparticle hydrogel that allows sustained release of vaccine components, increasing potency and duration of immune responses in mice. The hydrogel boosts antibody production with a 1,000-fold higher affinity for antigens.
Scientists have developed a controlled human hookworm infection model to accelerate vaccine development, with the goal of preventing infections that affect 576-740 million people worldwide. The study will evaluate two lead vaccine antigens and assess their efficacy in a phase II trial.
Researchers at Ohio State University developed a novel vaccine technique that induces antibodies against SARS-CoV-2 by boosting antigen production. In animal studies, the treatment successfully produced antibodies against the virus within a month.
Scientists at La Jolla Institute for Immunology discover that high-valency antigens can lead to a more-is-better immune system reaction, while low-valency antigens result in a smaller, more targeted B cell response. The study suggests that selecting antigens with the right valency will depend on the disease being targeted.
Researchers discovered that when the foreign antigen is more flexible, the germinal centre can employ a greater number of evolution strategies to make antibodies that bind foreign but not self-molecules. The study provides new insights for vaccine design and may help address the major roadblock in generating effective HIV vaccines.
A new vaccine candidate has been developed for HHV-6B, a virus that causes exanthem subitum in infants. The vaccine targets the gH/gL/gQ1/gQ2 complex and induces strong immunity against the virus. Animal experiments have shown that the vaccine prevents HHV-6B infection and activates dendritic cells to induce innate immunity.
Researchers found that women's reproductive secretions have a stronger effect on sperm performance in HLA dissimilar male-female combinations, indicating post-mating sexual selection. The study suggests that fertilization capability is dependent on immunogenetic compatibility between partners.
A new study demonstrates the potential of an intranasal vaccine platform using self-assembling peptide nanofibers tagged with antigens, inducing an immune response and activating T cells without adjuvants. This technology offers a safer and more effective alternative for generating long-lasting immunity against diseases.
The Michelson Prizes support the innovative work of Dr. Danika Hill and Dr. Michael Birnbaum on discovering targets for long-lived humoral immunity and identifying specific antigens in HIV vaccines.
Researchers at Tokyo University of Science developed a fully automated micro-lab on a chip that can quickly and reliably determine a patient's blood type. The device can dilute whole blood automatically and detect weak coagulation with the naked eye, holding potential for use in emergency medical situations.
A mouse study found that early exposure to vaccine- or microbiota-derived antigens significantly affects antibody diversity in adults. B-1 B cells, a subset of immune cells, were found to have diverse antibody responses in mice with normal gut microbiota versus those grown in sterile germ-free conditions.
Researchers used DNA origami to create virus-like particles coated with HIV proteins, eliciting a strong immune response from human B cells. The study found that the optimal spacing between antigens is wider than previously thought, contradicting common assumptions.
A new analysis confirms SARS-CoV-2 RBD as a specific target for antibody tests, with over 95% of patients developing antibodies within nine days. This suggests that RBD-based antigens could be used to estimate SARS-CoV-2 recovery rates and inform pandemic policies.
A new 15-minute antigen test for COVID-19 has shown high accuracy in detecting infected patients, potentially helping to identify new outbreak foci and implement quarantine measures. The test could also help screen healthcare workers and populations in low-income countries where molecular assays are limited.
Researchers have developed a fast and low-cost diagnostic test using inkjet-printed antibodies, potentially reducing coronavirus testing wait times to 30 minutes. The D4 assay tool has shown promise in detecting SARS-Cov-2 antigens with high accuracy, making it a promising solution for point-of-care diagnosis.
A new method developed by UC Santa Cruz researchers allows for the creation of libraries of probes for high-throughput assessments of T cell repertoires in blood samples. This technology has the potential to accelerate research and diagnostics in immunology, cancer immunotherapy, and COVID-19 response.
Researchers discovered a key role for H2-O chaperone protein in protecting the immune system from autoimmunity, which causes diseases such as multiple sclerosis and rheumatoid arthritis. The study found that the absence of H2-O disrupted normal helper T cell function, leading to autoimmune reactions.
Researchers Aarthi Narayanan and Remi Veneziano at George Mason University are developing a new vaccine design using DNA origami to deliver viral antigens. The customizability of the DNA structures enhances immunogenic potential while ensuring safety.
A new study has identified key mutations that affect Factor H binding protein (FHbp) on the surface of the meningococcus bacterium, which could lead to improved vaccines. The findings have major implications for current meningococcal group B vaccines, Trumenba and Bexsero.
Researchers at UC Santa Cruz have worked out the details of key molecular interactions involved in antigen selection and processing by MHC-I proteins. The new findings help explain puzzling differences among MHC-I proteins and suggest ways to manipulate them for diagnostic and therapeutic applications.
A team of researchers at the University of Rome Tor Vergata has developed a novel approach to build and dismantle DNA nanostructures using antibodies. They engineered DNA bricks with recognition tags that assemble in the presence of specific antibodies, enabling the creation of intelligent nanostructures with potential applications in ...
Scientists found that azoximer bromide increases the immunogenicity of anti-flu vaccines by tripling their efficiency. The study showed that this adjuvant helps the development of humoral and cell-mediated immune responses.
Researchers at Oak Ridge National Laboratory developed a method to isolate specific microbes from complex human oral microbiome samples using antibody engineering. They successfully isolated three different species of TM7 and another uncultivated bacterial group, SR1.
Researchers developed a kidney transplant risk model combining data from kidney donor registries, statistics of probable genetic profiles, and immunological knowledge to improve predictions of donor-recipient match. The study suggests that incorporating partial antigen match data can further enhance the accuracy of the model.
A study led by ISGlobal found that vaccination with RTS,S increases levels of antibodies recognizing 'P. falciparum' antigens not included in the vaccine, potentially leading to natural immunity. This effect was observed mainly in regions with low to moderate transmission levels.
Researchers at MIT developed a vaccine that dramatically enhances antitumor T cell population and allows cells to invade solid tumors. The booster vaccination increased the success rate of CAR-T cell therapy from 10% to 60% in mice, eliminating tumors in 60% of animals.
Researchers developed a nanotechnology-based compound that delivers an oral vaccine against hepatitis B to the immune system. The nanostructured silica protects the antigen from digestive acidity, enabling it to trigger an immune response. The study's results show promise for a polyvaccine against six diseases.
The Q-Plex Human Malaria Array measures multiple malaria antigens in a single sample, improving diagnosis sensitivity and supporting public health surveillance. This tool can help researchers develop more accurate RDTs and assess their performance.
Researchers at Northwestern University have designed spherical nucleic acids (SNAs) that stimulate powerful anti-cancer immune responses, completely eliminating tumors in 30% of animals and improving overall survival. The study's findings highlight the importance of chemical structure and three-dimensional presentation in vaccine design.